Bimode belongs to group of parenterally administered alkylating agent needed alone and in concomitant with other antineoplastic agents in the therapy of chronic lymphocytic leukaemia and refractory forms of non-Hodgkin lymphoma.
Bimode is a prescription drug which is used under the guidance of medical supervision
Bimode 100mg is indicated for the treatment of following condition;
Chronic lymphocytic Leukaemia
Indolent B-cell non-Hodgkin’s lymphoma
Mechanism of action
Bendamustine is type of alkylating agent. These agents are more active in the resting phase of the cell-cycle. There are various types of alkylating agents.
Bendamustine belongs to nitrogen mustard derivative and is active against resting as well as multiplying cells.
For chronic lymphocytic Leukaemia :
The recommended dose is 100mg/m2 IV infusion on days 1 and 2 of 28-day cycle, repeated for up to 6 cycles
Non-Hodgkin Lymphoma :
The recommended dose is 120mg/m2 IV infusion on days 1 and 2 of 21-day cycle repeated for upto 8 cycles
Side effects caused due to Bimode 100mg :
Decreased blood counts
Discontinue, if patients experience severe infusion reactions
While on treatment will causes Mild-mod renal impairment, mild hepatic impairment
Probably of anaphylactic/infusion reactions: serious in rare cases
Myelosuppression may report; decrease dose; restart treatment based on ANC and platelet count recovery; difficult situation of myelosuppression may lead to death
Check further fever and other signs of infection and treat promptly